Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 749-756

  Lianidou, Evriklia S ^a   Levesque, Michael A ^b   Katsaros, Dionyssios ^c   Angelopoulou, Katerina ^b   Yu, He ^d   Genta, Franco ^c   Arisio, Riccardo ^e   Massobrio, Marco ^c   Bharaj, Bhupinder ^b   Diamandis, Eleftherios P ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TURIN   (Italy)

^d Diagnostic Systems Laboratories Inc   (United States)

^e Ospedale Sant'Anna   (Italy)

Author keywords

DNA sequencing; Enzyme linked immunosorbent assay; Ovarian cancer; p53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; EXON; FEMALE; FRAMESHIFT MUTATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MUTATION; OVARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FLUOROIMMUNOASSAY; GENE EXPRESSION; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032927631     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984, 1991.
3. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, Yokota J: Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51: 5171-5176, 1991.
4. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard RCF: Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65: 40-44, 1992.
5. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, et al: Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513-1519, 1993.
6. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965, 1993.
7. McManus DT, Yap EP, Maxwell P, Russell SE, Toner PG, McGee JO: p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 174: 159-168, 1994.
8. Kim JW, Cho YH, Kwon DJ, Kim TE, Park TC, Lee JM, Namkoong SE: Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Gynecol Oncol 57: 199-204, 1995.
9. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE: An abundance of p53 null mutations in ovarian carcinoma. Oncogcne 13: 117-123, 1996.
10. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71: 587-597, 1992.
11. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
12. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C: p53 mutations in ovarian cancer: a late event? Oncogene 6: 1685-1690, 1991.
13. Kohler MF, Kerns BJM, Humphrey PA, Marks JR, Bast RC, Berchuck A: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81: 643-650, 1993.
14. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW: p53 gene analysis of ovarian borderline tumors and stage 1 carcinomas. Hum Pathol 26: 387-392, 1995.
15. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T: Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 70: 1191-1197, 1994.
16. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201-1208, 1995.
17. Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Cowther D: Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CM-1: correlation with histopathology and clinical features. Br J Cancer 69: 609-612, 1994.
18. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996.
19. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, et al: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693, 1996.
20. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, et al: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235, 1997.
21. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al: DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971-1981, 1996.
22. Hassapoglidou S, Diamandis EP, Sutherland DJA: Quantification of p53 protein in tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 8: 1501-1509, 1993.
23. Vojtesek B, Fisher CJ, Barnes DM, Lane DP: Comparison between p53 staining in tissue sections and p53 protein levels measured by an ELISA technique. Br J Cancer 67: 1254-1258, 1993.
24. Levesque MA, D'Costa M, Angelopoulou K, Diamandis EP: Immunofluorometric assay of p53 protein. Clin Chem 41: 1720-1729, 1995.
25. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP: Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327-1338, 1995.
26. Levesque MA, Tadross L, Diamandis EP, D'Costa M: Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. Am J Clin Pathol 107: 308-316, 1997.
27. Joypaul BV, Vojtesek B, Newman EL, Hopwood D, Grant A, Lane DP, Cuschieri A: Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathol 23: 465-470, 1993.
28. International Federation of Gynecology and Obstetrics. Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 56: 263-264, 1987.
29. Serov SF, Scully RF: Histological typing of ovarian tumors. In: International histological classification of tumors. Geneva, World Health Organization, 1973, 56pp.
30. Strauss WM: Preparation of genomic DNA from mammalian tissues. In: Current protocols in molecular biology (Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds). New York, John Wiley and Sons, 1995, 2.2.1-2.2.3.
31. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, et al: p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet 10: 188-193, 1995.
32. Bharaj BS, Angelopoulou K, Diamandis EP: Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clin Chem 44: 1397-1403, 1998.
33. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, et al: Database of p53 gene mutations in human tumors and cell lines: updated compilation and future prospects. Nucl Acids Res 25: 151, 1997.
34. Angelopoulou K, Levesque MA, Katsaros D, Shipman R, Diamandis EP: The exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clin Chem 44: 72-77, 1998.
35. Jego N, Thomas G, Hamelin R: Short direct repeats flanking deletions, and duplicating insertions in the p53 gene in human cancers. Oncogene 8: 209-213, 1993.
36. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89: 7262-7296, 1992.